Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2029961 | 0.84 | PER2 (0.35) | PER2 | |
| SCHEMBL2034868 | 0.80 | PER2 (0.35) | PER2 | |
| SCHEMBL2743813 | 0.79 | PER2 (0.35) | PER2 | |
| SCHEMBL2035372 | 0.76 | PDK2 (0.33) | — | |
| SCHEMBL2030869 | 0.73 | PER2 (0.31) | PER2 | |
| SCHEMBL27112747 | 0.67 | P2RX7 (0.35) | PER2 | |
| SCHEMBL17487067 | 0.67 | TP53 (0.39) | PER2 | |
| SCHEMBL17487068 | 0.67 | TP53 (0.39) | PER2 | |
| SCHEMBL2037183 | 0.65 | P2RX7 (0.39) | PER2 | |
| SCHEMBL2034493 | 0.64 | PTGER4 (0.36) | PER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2485314-A1 | Nonaqueous electrolytic solution and nonaqueous electrolyte secondary cell | Mitsubishi Chemical Corporation (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-8178246-B2 | Nonaqueous electrolyte solution, nonaqueous electrolyte secondary cell, and carbonate compounds | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-05-15 | — | — | US | disclosed |
| EP-2339684-A2 | Nonaqueous electrolytic solution, nonaqueous electrolyte secondary cell, and carbonate compounds | Mitsubishi Chemical Corporation (JP) | 2011-06-29 | — | — | EP | disclosed |
| US-20090253048-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY CELL, AND CARBONATE COMPOUNDS | MITSUBISHI CHEMICAL CORPORATION (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-1890357-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY BATTERY AND CARBONATE COMPOUND | Mitsubishi Chemical Corporation (JP) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253048-A1 | NONAQUEOUS ELECTROLYTE SOLUTION, NONAQUEOUS ELECTROLYTE SECONDARY CELL, AND CARBONATE COMPOUNDS | SLC9A1, NHERF1, CA2 | PER2 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.